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It appears that serum creatinine measurements were generated from both an ambulatory and an acute care environment and transferred to the pharmacists. Serum creatinine can vary dramatically from day to day for patients in a hospital (e.g., presence of dehydration, acute renal dysfunction, etc.). The authors do allude to this in their methods by reporting follow-up eGFR to the pharmacists. However, acutely reduced GFR could have accounted for an important subset of the pharmacist alerts that were not accepted by the prescriber. It would be important to consider this in the analysis and analyze the data omitting those alerts generated only from in-hospital patient stays.
New prescriptions and ongoing prescriptions should be considered separately. Were the alerts handled the same for both? For example, the risk of hypokalemia differs for a patient who has successfully tolerated a given dosage of a diuretic for a year or more with stable -albeit reduced -renal function compared to a patient who is being newly-initiated on a diuretic at that same dosage. Resistance on the part of the prescriber to accept the recommended dosing change may differ between new and ongoing prescriptions as well. Both these reasons contribute to the need to separate the analysis for new and ongoing prescription alerts.
It is stated that two pharmacists independently evaluated all medication errors on the potential to cause an ADE. Were these two pharmacists also pharmacists who were involved in receiving the alerts/contacting the prescribers? If so, there is potential for bias in their evaluation of the risks of ADE.
A question related to the above point is, how were discrepancies between the two pharmacists" evaluation handled?
How was the threshold of <= 40 ml/min/1.73m2 chosen? Various thresholds have been used in older studies (see Table 1 in Long CL et al. Compliance with Dosing Guidelines in Patients with Chronic Kidney Disease. Ann Pharmacother. 2004; 38:853-8. PMID: 15054147) . Additionally, drugs can have specific, different creatinine clearance thresholds stated in the product labeling (e.g., < 51, < 30, < 15, or no specific threshold) (see examples in Table 1 Related to the above point, it would be appropriate, if possible, to assess how the results differ when a different threshold is applied. For example, can the results be re-evaluated to determine what the number and potential severity changes would be based on specific thresholds for specific drugs (or at least for a subset)?
Additional information about the technical details of how the laboratory reports were automatically sent to the pharmacists would be useful to many readers. While one sentence is devoted to this in the methods, those who work in this arena know how difficult this can be to set up and execute and the specifics of "how you did it" can be helpful to others.
Please include the source/reference of the classification of the severity of the medication error. RESULTS & CONCLUSIONS A brief mention in the results of which drugs" had a higher % of pharmacist recommendations rejected would be of interest to the reader.
GENERAL COMMENTS
This is a clinically important and timely topic. The authors are to be commended for implementing an intervention of this type. Such interventions are challenging and time-consuming to implement and maintain in such a real-world situation as theirs.
The fact that the alert appeared each time there was a new prescription is an important design feature for sustainability.
While MDRD is certainly better for estimating eGFR than is serum creatinine, nearly all drug dosing guidelines in product labeling for patients with reduced renal function are based on serum creatinine measurement data with calculated GFR using the Cockcroft Gault equation. The implications of this for this project should be discussed.
The "implications for clinical practice" section provides important and compelling discussion. Specifically, more information is needed on process of identifying ADEs, including whether the reviewers were blinded to the original exposure and changes/lack of changes to the drug regimen after pharmacist recommendations; whether this search was conducted by multiple reviewers with determination of their agreement. 2. In the abstract, ADEs should be specifically described as limited to those identified through hospital record review. 3. The written English needs a bit of editing. RESULTS & CONCLUSIONS the ADEs are an issue. More complete information should be provided on the process of identifying them and they should be more accurately described as limited to those identified in hospital records.
Specific Comments

GENERAL COMMENTS
It would be helpful to include more information on the medical errors identified by the pharmacists, including the frequency of various categories such as drug/drug interactions, dosing errors, inadequate monitoring, etc. Author"s reply: We agree with the reviewer that a more complex study design (for example with a "before and after design" or including a comparison group) would have strengthened our findings. With interest we have read the suggested literature of the reviewer.
VERSION 1 -AUTHOR RESPONSE
According to the reviewers comments and in the light of the study of Bhardjawa et al, we added the following line of reasoning to the limitation section in the discussion (see page 15). In addition, we now refer to this study in the second paragraph of the Discussion (section on "Comparison with other studies") (see page 13) and reference list (number 36, page 24).
It now reads:
"First, our study design does not allow determining individual health care effects, nor overall costbenefits. This would necessitate a more complex study design as was for example used in the population-based randomized controlled renal drug alert effectiveness trial of Bhardwaja et al, or a "before and after" design ."
Two recent studies, also concerning subjects with renal impairment, identified drug-related problems due to inappropriate prescriptions in over 20% of the patients.18,36
2. It appears that serum creatinine measurements were generated from both an ambulatory and an acute care environment and transferred to the pharmacists. Serum creatinine can vary dramatically from day to day for patients in a hospital (e.g., presence of dehydration, acute renal dysfunction, etc.). The authors do allude to this in their methods by reporting follow-up eGFR to the pharmacists. However, acutely reduced GFR could have accounted for an important subset of the pharmacist alerts that were not accepted by the prescriber. It would be important to consider this in the analysis and analyse the data omitting those alerts generated only from in-hospital patient stays.
Author"s reply (part 1): We agree with the reviewer that in acute setting renal function can change dramatically. Therefore, in our study GFR<40-alerts were restricted to patients in the ambulatory setting. So, for clarity, clinical (in-hospital) laboratory data were not included in the original study design and therefore serum creatinine/eGFR measurements of the emergency room and other hospital wards were not taken into account.
We thank the reviewer for her valuable comment, as it made us realize that in the methods we need to emphasize more that eGFR-alerts were restricted to ambulatory patients. The methods and conclusions of the Abstract (see page 4) as well as Methods and Conclusions in the manuscript (see page 6 and page 16) were changed and now read as follows:
Participants-All adults who underwent ambulatory creatinine measurements which triggered an eGFR≤40-alert. Primary and secondary outcome measures-The total number of ambulatory subjects with an eGFR≤40-alert during the study period of one year and the number of medication errors related to renal impairment….. etc Conclusions-The introduction of automatic eGFR-alerts identified a considerable number of subjects who are at risk for ADEs due to renal impairment in an ambulatory setting…. etc
Design and case-finding This prospective observational study was conducted between February 1st 2009 and January 31st 2010. During this period, all consecutive adults in whom a serum creatinine was measured in the ambulatory setting and who had an eGFR at or below the cut-off point of 40 ml/min/1.73 m2 were identified, irrespective of the reason for laboratory testing. This threshold was based on guidelines advising dosage adjustment in renal impairment and also chosen from a practical point of view.25,26 A higher cut-off-point of 50-60 ml/min/1.73 m2 was expected to exceed an acceptable workload, and the generation of many alarms induces the risk of ignoring and overriding alerts.40,43-45 Each week the laboratory automatically reported on ambulatory patients with an eGFR ≤40 ml/min/1.73 m2 to the pharmacists.
Conclusions
The introduction of automatic renal function alerts in the ambulatory care setting, with the involvement of both GPs and community pharmacists, revealed that a considerable part of the population is at risk for ADEs due to impaired renal function….etc.
Author"s reply (part 2): In addition, we evaluated how often the eGFR<40 alert concerned an acute deterioration of the eGFR. We identified only 3 cases with eGFR<40 alert concerned an AKI in the context of an acutely ill patient. One patient was admitted to the hospital after laboratory results were known, one patient was sent to an internal specialist at an emergency outpatient clinic and one patient appeared terminally ill. Therefore, overall, acutely reduced eGFR did not account for an important subset of the eGFR<40 alerts in the ambulatory setting.
To make the readers more aware of this subset of data, we added a sentence to the Results section (see page 11):
It now reads:
In some cases, the recovery of renal function was expected or underestimation of renal function was presumed, both of which were generally checked with a 24-hour creatinine clearance. Overall, acutely reduced eGFR did not account for an important subset of the eGFR<40 alerts towards the community pharmacists (n=3).
3. New prescriptions and ongoing prescriptions should be considered separately. Were the alerts handled the same for both? For example, the risk of hypokalaemia differs for a patient who has successfully tolerated a given dosage of a diuretic for a year or more with stable -albeit reducedrenal function compared to a patient who is being newly-initiated on a diuretic at that same dosage.
Resistance on the part of the prescriber to accept the recommended dosing change may differ between new and ongoing prescriptions as well. Both these reasons contribute to the need to separate the analysis for new and ongoing prescription alerts.
Authors reply: We had many thoughts about how to tackle this relevant point. The main objective of this study was to report the total number of eGFR-alerts and medication errors related to renal impairment in a 1-year period. Relevant to the reviewer"s question is the fact that the alerts were reviewed by the pharmacists. Irrespective of the type of prescription (new or ongoing prescription) they gave a recommendation to the prescribing physician. So, both type of prescriptions were handled on equal footing by the pharmacists. As a secondary outcome we reported the acceptance rate of the recommendations by the physicians. This rate (76%) might have been influenced by the type of prescription, as correctly suggested by the reviewer. To analyse the physicians" adherence in-depth, would require focussing on the prescribing physicians and their decision making process (with also taking into account other variables like dosage, co-morbidities, past experiences, etcetera). So, although very interesting, we think the influence of the type of prescription cannot be addressed properly with our data.
To make the readers more aware of the influence of non-adherence of physicians on the overall efficiency of the eGFR-alert, we added the following sentence to the revised manuscript (Discussion, section "strenghts and weaknesses of the study", see page 15):
"However, to improve the overall efficiency of the eGFR-alerts, also variables influencing physicians" (non) adherence towards pharmacists" recommendations (like type and duration of medication use) should be further studied."
4. It is stated that two pharmacists independently evaluated all medication errors on the potential to cause an ADE. Were these two pharmacists also pharmacists who were involved in receiving the alerts/contacting the prescribers? If so, there is potential for bias in their evaluation of the risks of ADE.
Author"s reply: Yes, the two pharmacists (KB and EP) were also involved in the data collection. In the conceptualisation of the study we have therefore taken several measures to minimize the risk of bias in their evaluation of potential ADEs. 1. From all pharmacies the medication errors were collected by the first author (HJ, not a pharmacist and not involved in the generation of eGFR-alerts nor the recommendations towards physicians) and put together in one database. For the evaluation of potential ADEs this database was made anonymous by the first author (HJ). 2. This anonymous database was sent to the two evaluating pharmacists (KB and EP) only after completing the data collection (> 1 year), limiting the potential that they could recall past medication errors they had been involved in.
To make the readers more aware of our protocol we added the following sentence to the Methods, section Classification and tracking of (potential) ADEs" (see page 8):
"To evaluate the impact of eGFR40-alerts two pharmacists (EP and KB) independently evaluated all medication errors on the potential to cause an ADE (defined as a potential ADE (pADE)). They received a database that was anonymized by an investigator not involved in the eGFR-alert processing (HJ)." 5. A question related to the above point is, how were discrepancies between the two pharmacists" evaluation handled?
Author"s reply: Overall, the pharmacists had different classification of the potential severity of the ADE in 7% (n=21). These discrepant judgments were discussed with the two pharmacists and two nephrologists (HJ and HB) to reach consensus. Final decisions were based on Dutch guidelines (including "the National Formulary on drug prescribing in renal impairment" and the "National Shared Care Guidelines on Chronic Kidney Disease (CKD). The likelihood of side effects (based on clinical experience) was sometimes also taken into account. An example of a discrepant judgement was the following case: in a 81 year old patient with an eGFR of 39 ml/min/1.73m2 levocitirizine (antihistamine drug) 10 mg once daily was prescribed (guidelines state a maximum of 5 mg every other day in eGFR 30-49 and 5 mg every three days in eGFR 10-29). One pharmacist classified this as a serious potential ADE ("Altered mental status due to sedation"), based on the increased risk of sedative side effects due to renal impairment and high dose. The other pharmacist classified it as potentially life threatening ("Decline in mental status with risk of falling"), also taking into account the age of the patient. In case of this example we classified levocitirizine 10 mg once daily as a serious pADE, However, if eGFR would have been <30, we agreed that we would have classified it as a potential life threatening pADE (based on the degree of overdose and the risk of falling due to high age).
To clearify how discrepancies between the two pharmacists" evaluation were handled, the section on "classification and tracking of (potential) adverse drug effect" (Methods, page 8) was changed and now reads as follows:
"To evaluate the impact of eGFR40-alerts two pharmacists (EP and KB) independently evaluated all medication errors on the potential to cause an ADE (defined as a potential ADE (pADE))…<…> To reach a consensus, all discrepant ratings were discussed with both pharmacists and two nephrologists (HB and HJ).
6. How was the threshold of <= 40 ml/min/1.73m2 chosen? Various thresholds have been used in older studies (see Table 1 AJKD 2010; 56:809-12) . 3. At the start of our project, the exact cut-off point for drug adjustments in renal impairment was still discussed in the Dutch transmural guideline committee for CKD, and exact thresholds were not definitely chosen yet. As a cut-off value of 40 ml/min/1.73m2 was proposed in the guideline committee (personal communication HB) at the writing of the study protocol, we decided to follow this threshold. As a matter of fact, eventually a more detailed advice was given in the current guideline with specific eGFR thresholds (between <80-<30) for 40 commonly used drugs (De Grauw WJC et al. Huisarts Wet 2009; 52:586-97) .
As the reviewer highlights, various thresholds have been used in other studies. An eGFR ≤40 ml/min/1.73m2 seems a safe and feasible cut-off in clinical practice, but a cut-off of ≤50 or 60, or drug specific thresholds could have been used. Cut-offs for dosage adjustment vary between different guidelines and (to increase complexity) these guidelines use various measures for renal function (e.g. creatinine clearance, eGFR MDRD, Cockcroft-Gault).
We agree with the reviewer that it is important to underline these cut-off issues in the manuscript. We therefore explain and discuss the threshold of 40, as well as the varying thresholds in the literature in more detail in the Methods (section "design and case-finding", page 6) and Discussion (page 16). We added the literature suggestions of the reviewer to the manuscript (Reference list, number 36 and 56, page 24 and 25). In addition a Supplemental table was created (see our reply to comment 7 of reviewer 1).
It now reads:
Methods "… During this period, all consecutive adults in whom a serum creatinine was measured in the ambulatory setting who had an eGFR at or below the cut-off point of 40 ml/min/1.73 m2 were identified, irrespective of the reason for laboratory testing. This threshold was based on guidelines advising dosage adjustment in renal impairment25,26 and also chosen from a practical point of view. A higher cut-off-point of 50-60 ml/min/1.73m2 was expected to exceed an acceptable workload, and the generation of many alarms induces the risk of ignoring and overriding alerts." Discussion ". Finally, we chose for a safe, but also feasible threshold for renal function alerts. However, as thresholds for dosage adjustment vary between different guidelines, a higher cut-off of ≤50 or 60 ml/min/1.73m2, or drug specific thresholds could be discussed.25,26,36,56 …… …... Some guidelines advise a higher cut-off point for dose adjustments (creatinine clearance 50-60 ml/min),11,61 but this was expected to result in an amount of alerts exceeding an acceptable workload. Moreover, as the MDRD tends to underestimate true GFR, we presumably already included subjects with true GFR >40ml/min.62" Nota Bene: we would like to emphasize, that by using a relatively low cut-off point, the amount of work in this study remained limited for most of the participating health care workers. We wanted to test an easily implementable intervention, irrespective of the cut-off point used. Changing the attitude and working practices of health care workers is no easy feat. Introducing a change combined with a hefty increase in workload would not have helped in the acceptance. Still, within our region, the discussion is ongoing, whether the alert cut-off point should be increased. How choices in that aspect will develop, is both dependent upon proposed changes in the regional protocols or on country wide developments in the Netherlands.
7. Related to the above point, it would be appropriate, if possible, to assess how the results differ when a different threshold is applied. For example, can the results be re-evaluated to determine what the number and potential severity changes would be based on specific thresholds for specific drugs (or at least for a subset)?
Author"s reply: The reviewer raises a very interesting question, which also has interface with the feasibility of applying different thresholds in daily clinical practice (see author reply 6, reviewer 1). From our current database it was not possible to extrapolate the number and potential severity of ADEs based on different thresholds of eGFR, because automatic alerts (and related data) other than eGFR≤40 were not generated in the study period (2009) (2010) .
However, for the study period we managed to track the exact number of patients with renal impairment according to different eGFR cut-offs. By this means, we created insight in the (roughly estimated) expected workload with varying thresholds of eGFR.
We summarized these data in a supplemental table (B), which we would like to add as an addendum to the manuscript (see uploaded file).
We now refer to Supplemental table B in the section on "Effectiveness: workload and time investment of pharmacists" in the results (page 12) which now reads:
"Retrospectively we evaluated the feasibility of different thresholds for kidney function alerts by calculating the number of low eGFR-alerts that would have been generated during the study period using different cut-offs for renal impairment (<30, <50 and <60 ml/min/1.73m2, respectively, see Supplemental table B)."
8. Additional information about the technical details of how the laboratory reports were automatically sent to the pharmacists would be useful to many readers. While one sentence is devoted to this in the methods, those who work in this arena know how difficult this can be to set up and execute and the specifics of "how you did it" can be helpful to others.
Author"s reply: We agree with the reviewer. We summarized additional information about the technical details of the generation of the eGFR-alerts and now present them as a Supplemental table (C).
Supplemental table C. Technical details of automatic laboratory alerts
In the management database system of our laboratory the relationship and indexes of different types of data are embedded. We defined a query in this database to select our study population. This query included: testcode (eGFR), ambulatory laboratory requests (excluding clinical eGFR data), and data were filtered on age ≥18, eGFR ≤45 and zip codes of the city of Zwolle. The query was run periodically (weekly). A module matching the patients" unique Citizens Service Number (CSN) with the patient"s pharmacy code was developed for this project, which enabled us to address the eGFRalerts to the right community pharmacy. The fact that in The Netherlands patients are generally registered at one single community pharmacy (en thus have a one personal pharmacy code) facilitates this method.
9. Please include the source/reference of the classification of the severity of the medication error.
Author"s reply: The article describing the classification of the severity of medication errors is: Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors; detection and classification methods. Qual Saf Health Care 2004; 13;306-14.
We included the reference in the Methods (see page 8) and Reference list (number 29, page 24):
Classification and tracking of (potential) adverse drug events To evaluate the impact of eGFR40-alerts two pharmacists (EP and KB) independently evaluated all medication errors on the potential to cause an ADE (defined as a potential ADE (pADE)) using a methodology developed for classification of medication errors and (p)ADEs.29 10. A brief mention in the results of which drugs" had a higher % of pharmacist recommendations rejected would be of interest to the reader.
Author"s reply: The majority of rejected recommendations included diuretics and renin-angiotensinaldosterone system blockers. We added the suggestion of the reviewer to the results (page 11) with now reads as follows: "The majority of rejected recommendations included diuretics and renin-angiotensin-aldosterone system (RAAS) blockers like ACE inhibitors and ARB drugs."
11. Other General Comments -This is a clinically important and timely topic. The authors are to be commended for implementing an intervention of this type. Such interventions are challenging and time-consuming to implement and maintain in such a real-world situation as theirs.
-The "implications for clinical practice" section provides important and compelling discussion.
-The fact that the alert appeared each time there was a new prescription is an important design feature for sustainability.
Author"s reply: we thank the reviewer for these encouraging notes -While MDRD is certainly better for estimating eGFR than is serum creatinine, nearly all drug dosing guidelines in product labelling for patients with reduced renal function are based on serum creatinine measurement data with calculated GFR using the Cockcroft Gault equation. The implications of this for this project should be discussed. Author"s reply: In comment 6 we shortly touched on the above point raised by the reviewer, but here we evaluate the implications of different measurements of renal function more in detail. Overestimates of renal function may lead to administration of inappropriately large doses and possible toxicity, and, conversely, underestimates may lead to subtherapeutic dosing and treatment failure. Currently, no estimation equation provides accurate estimated for áll patients. As the reviewer highlights, the FDA "Guidance for industry; pharmacokinetics in patients with impaired renal function", published in 1998, indeed recommends the use of the CG for pharmacokinetic studies and drug dosing recommendations. At that time, the CG was the most commonly used formula to estimated renal function. However, at the time this study was initiated, the MDRD was recommended as the preferred . These studies the MDRD is a reasonable alternative to the CG for drug dosing. This is supported by the article of) who gave a timeline of the development of estimating equations and reviewed the implications for drug dosing.
We discussed these considerations in the limitation section (page 16) of the discussion which now reads as follows:
Strenghts and weaknesses of the study "… Finally, we chose for a safe, but also feasible threshold for renal function alerts. However, as thresholds for dosage adjustment vary between different guidelines, a higher cut-off of ≤50 or 60 ml/min/1.73m2, or drug specific thresholds could be discussed. 25, 26, 36, 56 Besides, as the CockcroftGault (CG) formula is often used in pharmacokinetic studies and for drug dosing recommendations, the implications of the use of renal function estimates like the MDRD equations for drug dosing, is under debate. Several studies have compared drug dosing recommendations based on the CG with those based on the MDRD.57-59 In summary, the accuracy of the MDRD seems comparable to the CG.57-59 Based on these studies, in our opinion, the MDRD is a reasonable alternative to the CG for drug dosing. This is of importance especially since there is an increasing trend of clinical laboratories reporting the MDRD along with serum creatinine, which is also recommended by national and international organizations. 26,60"
12. Specific Comments - Table 4 could be deleted as the information is presented in the text.
Author"s reply: We agree with the reviewer and deleted table 4.
- Figure 1 could be deleted.
Author"s reply: We deleted Figure 1 . 1. A few aspects of the methods require additional information. Specifically, more information is needed on process of identifying ADEs, including whether the reviewers were blinded to the original exposure and changes/lack of changes to the drug regimen after pharmacist recommendations; whether this search was conducted by multiple reviewers with determination of their agreement.
Author"s reply: We thank the reviewer for his comments and agree that the methodological description of the process we used to identify ADEs was brief.
1) Regarding the process of identifying ADEs:
The two nephrologists (HJ and HB) independently reviewed the hospital records (starting in 2011) of all subjects in whom a medication errors was detected. Of those who had been admitted, HJ and HB reviewed all admission and discharge diagnoses to check for ADEs. The relationship of the ADE with the "suspected" agent was double checked by evaluating whether the medication regimen at admission in the hospital record matched with the medication regimen in the pharmacy record at the date of admission.
2) Regarding blinding of the ADE reviewers to the original exposure:
The two nephrologists (HJ and HB) were not involved in processing the eGFR-alerts (2009) (2010) . Their job was to review (in 2011) ADEs in all patients with medication errors. It could be argued that with this design, they were not "blinded" to the original variables. However, we do not expect this had major impact on the conclusions of our clinical survey.
3) Regarding the question whether the search was conducted by multiple reviewers and the determination of their agreement: After independent review of the hospital records the two nephrologists (HJ and HB) discussed their findings. There was disagreement and subsequent discussion in 3 cases. Hospital records of these cases were reviewed together for reaching consensus.
With regard to improvement of the definition and description of ADEs, we also refer to our reply on comment 4 of reviewer 2.
We extended the process of identifying ADEs in the revised manuscript to improve clarity. This paragraph in the Methods (page 8) now reads as follows:
"The best assessment of the number of ADEs proved to be from the documentation on ADEs in the hospital records.30 Therefore, one year after the end of the study, the hospital records of all subjects in whom a medication error was detected, were reviewed. This review was performed by two nephrologists (HJ and HB) who independently checked the occurrence of ADEs. ADEs were based on admission and discharge diagnosis in the patients" medical records. The relationship of the ADE with the "suspected" agent was double checked by evaluating whether the medication regimen at admission in the hospital record matched with the pharmacy record at the date of admission. After review of the hospital records HJ and HB discussed their findings for reaching consensus."
2. In the abstract, ADEs should be specifically described as limited to those identified through hospital record review.
Author"s reply: We added this suggestion in both the abstract as well as the methods and results (page 4, 8 and 11 respectively), which now read as follows:
Abstract Primary and secondary outcome measures-"…Classification of all medication errors on their potential to cause an adverse drug event (ADE) and the actual occurrence of ADEs (limited to those identified through hospital record review) one year after the introduction of the alerts were measured."
Methods Classification and tracking of (potential) adverse drug events "The best assessment of the number of ADEs proved to be from the documentation on ADEs in the hospital records.30 Therefore, one year after the end of the study, the hospital records of all subjects in whom a medication error was detected, were reviewed. This review was performed by two nephrologists (HJ and HB) who independently checked the occurrence of ADEs. ADEs were based on admission and discharge diagnosis in the patients" medical records. The relationship of the ADE with the "suspected" agent was double checked by evaluating whether the medication regimen at admission in the hospital record matched with the pharmacy record at the date of admission. After review of the hospital records HJ and HB discussed their findings for reaching consensus."
Results "Overall, 40 ADEs were identified in hospital records within one year in the group of subjects with a medication error, including …" 3. The written English needs a bit of editing.
Author"s reply: We felt that the written English of our manuscript needed to be of good quality for publication in BMJ Open. Therefore the complete manuscript has been reviewed by a professional (native speaker) translator [A.A.Starreveld, B.Ed, B.
A.] and changes were made throughout the complete manuscript. In addition, the article has been accurately read by two experienced medical translation reviewers. Their feedback and comments are also incorporated in the revised manuscript. These linguistic changes are present throughout the manuscript and are highlighted.
4. As described above, the ADEs are an issue. More complete information should be provided on the process of identifying them and they should be more accurately described as limited to those identified in hospital records.
Author"s reply: Concerning this comment we would like to refer to our reply on the first comment of this reviewer, which also includes more detailed information on the process of identifying ADEs.
With regard to the definition of our ADEs, we now describe them in more detail in both the Abstract as well as the Methods and Results (page 4, 8 and 11, respectively), which now read as follows:
Results "Overall, 40 ADEs were identified in hospital records within one year in the group of subjects with a medication error, including …" 5. It would be helpful to include more information on the medical errors identified by the pharmacists, including the frequency of various categories such as drug/drug interactions, dosing errors, inadequate monitoring, etc.
Author"s reply: We agree with the reviewer. To provide more in-depth information on the type of drug errors that were detected, we created a new figure (figure 4 ) which gives an overview of the various errors that were identified by the pharmacists.
We included the following sentence to the Results (page 10), section on "number and type of medication errors".
Number and type of medication errors "…An overview of the type of drug errors that were identified by the pharmacists is given in figure 4 ." 
GENERAL COMMENTS
The authors have done a nice job of addressing the reviewers' critiques.
